We improve lives.
Latest News
-
June 25, 2026 | News
Why Gout’s Straightforward Biology and Large Unmet Need Make It an Overlooked Drug Development Opportunity, says Dr James Mackay, Crystalys Therapeutics CEO
-
June 23, 2026 | News
BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys’ experienced team wants to change that
-
June 1, 2026 | News
Attacking Gout: Crystalys Sees Room for Its Dotinurad and Other Allopurinol Alternatives
-
May 26, 2026 | Press Releases
Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout